Dysregulation of HIF and VEGF is a unifying feature of the familial hamartoma syndromes (Q35839675)

10 August 2017

1 reference

title

Dysregulation of HIF and VEGF is a unifying feature of the familial hamartoma syndromes (English)

1 reference

10 August 2017

1 reference

2

William G Kaelin

1 reference

10 August 2017

James Brugarolas

1

1 reference

10 August 2017

publication date

1 July 2004

1 reference

10 August 2017

1 reference

10 August 2017

volume

6

1 reference

10 August 2017

issue

1

1 reference

10 August 2017

page(s)

7-10

1 reference

A serine/threonine kinase gene defective in Peutz-Jeghers syndrome

10 August 2017

cites work

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.CCR.2004.06.020

Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.CCR.2004.06.020

mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.CCR.2004.06.020

The AMP-activated protein kinase cascade--a unifying system for energy control

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.CCR.2004.06.020

Oncogenic alterations of metabolism

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.CCR.2004.06.020

The phosphoinositide 3-kinase pathway

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.CCR.2004.06.020

Gleevec: prototype or outlier?

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.CCR.2004.06.020

LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR-1

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.CCR.2004.06.020

The LKB1 tumor suppressor negatively regulates mTOR signaling

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.CCR.2004.06.020

Akt regulates growth by directly phosphorylating Tsc2

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.CCR.2004.06.020

How oxygen makes its presence felt

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.CCR.2004.06.020

Molecular genetic advances in tuberous sclerosis

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.CCR.2004.06.020

Cancer. Addiction to oncogenes--the Achilles heal of cancer

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.CCR.2004.06.020

Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.CCR.2004.06.020

Activation of translation complex eIF4F is essential for the genesis and maintenance of the malignant phenotype in human mammary epithelial cells

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.CCR.2004.06.020

Complexes between the LKB1 tumor suppressor, STRAD alpha/beta and MO25 alpha/beta are upstream kinases in the AMP-activated protein kinase cascade

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.CCR.2004.06.020

PTEN: one gene, many syndromes

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.CCR.2004.06.020

Loss of tuberin, the tuberous-sclerosis-complex-2 gene product is associated with angiogenesis

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.CCR.2004.06.020

TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.CCR.2004.06.020

Hamartomatous polyposis syndromes: molecular genetics, neoplastic risk, and surveillance recommendations

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.CCR.2004.06.020

Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.CCR.2004.06.020

Mutation in TSC2 and activation of mammalian target of rapamycin signalling pathway in renal angiomyolipoma

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.CCR.2004.06.020

Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.CCR.2004.06.020

The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.CCR.2004.06.020

Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.CCR.2004.06.020

Vascular abnormalities and deregulation of VEGF in Lkb1-deficient mice

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.CCR.2004.06.020

Loss of the Lkb1 tumour suppressor provokes intestinal polyposis but resistance to transformation

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.CCR.2004.06.020

The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.CCR.2004.06.020

eIF-4E expression and its role in malignancies and metastases.

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.CCR.2004.06.020

eIF4E--from translation to transformation

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.CCR.2004.06.020

Will mTOR inhibitors make it as cancer drugs?

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.CCR.2004.06.020

TSC2 regulates VEGF through mTOR-dependent and -independent pathways

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.CCR.2004.06.020

Peutz-Jeghers syndrome is caused by mutations in a novel serine threoninekinase

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.CCR.2004.06.020

The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.CCR.2004.06.020

LKB1 is the upstream kinase in the AMP-activated protein kinase cascade

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.CCR.2004.06.020

TSC2 mediates cellular energy response to control cell growth and survival

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.CCR.2004.06.020

Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.CCR.2004.06.020

LKB1, a protein kinase regulating cell proliferation and polarity

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.CCR.2004.06.020

Signaling control of mRNA translation in cancer pathogenesis

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.CCR.2004.06.020

Protein elongation factor EEF1A2 is a putative oncogene in ovarian cancer

1 reference

12 October 2022

https://opencitations.net/index/coci/api/v1/references/10.1016/J.CCR.2004.06.020

Identifiers

DOI

10.1016/J.CCR.2004.06.020

1 reference

10 August 2017

1 reference